Course Opens
05/08/2025 at 12:15 PM EST
Credits
1
Credit Expires
05/28/2025
Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings.
In this CEC Oncology live, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity management, and individualizing disease treatment across the patient’s lifespan.
At the conclusion of this activity, learners will be able to better:
This program is supported through independent educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.
Neuro-oncologists, general oncologists, general neurologists, pediatric oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
☒ Care Continuum
☒ Oncology Nursing Practice
☒ Psychosocial Dimensions of Care
☒ Symptom Management, Palliative Care, Supportive Care
☒ Treatment
CBCN®
☒ Care Continuum
☒ Psychosocial Dimensions of Care
☒ Treatment
CPHON®
☒ Care Continuum
☒ Care of the Pediatric Hematology and Oncology Patient
☒ Psychosocial Dimensions of Care
☒ Symptom Management, Palliative Care, Supportive Care
☒ Treatment
AOCNP®
☒ Care Continuum
☒ Professional Practice/Performance
☒ Psychosocial Dimensions of Care
☒ Roles of the APRN
☒ Symptom Management, Palliative Care, Supportive Care
☒ Treatment
BMTCN®
☒ Professional Practice/Performance
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CE Concepts, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Hirbe reports the following financial relationships:
Advisory Board: Aadi Subsidiary, Inc.
Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.
Grants: Tango
Other financial or material support: Boehringer Ingelheim
Dr. Moertel reports the following financial relationships:
Advisory Board and Consultant: Alexion Pharmaceuticals, Inc./AstraZeneca and SpringWorks Therapeutics, Inc.
Research Support: Alexion Pharmaceuticals, Inc.
Speakers Bureau: Alexion Pharmaceuticals, Inc./AstraZeneca
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Margaret Wright, BSN, RN (Peer Reviewer)
David Modrak, PhD (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
MM-153-050825-90
Call us at 859-260-1717 • info@ceconcepts.com
